SenzaGen to present at Vator Securities Unicorn Summit on May 8, 2018

SenzaGen announces that the company will participate in the Vator Securities Unicorn Summit, which takes place in Stockholm in May. Anki Malmborg Hager, CEO, will present the company developments and SenzaGen’s ongoing and planned activities for commercialization of GARD – a technology platform that allows for replacement of animal experiments with genetic testing to assess whether the chemicals we come into contact with in our daily lives are allergenic.

Unicorn Summit is a capital market day organized by Vator Securities to bring together some of the most innovative and fast-growing Swedish life science companies with investors. More information about Vator Securities www.vatorsecurities.se

 

For more information, please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822

 

About GARD™
GARD is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have over 90 percent reliability.

This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75 percent. SenzaGen’s tests are also capable of measuring the potency of a substance’s allergenic properties. Consequently, GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.

About SenzaGen
SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company’s patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit www.senzagen.com

SenzaGen AB are listed on Nasdaq First North in Stockholm and FNCA is the company’s Certified Adviser. For more information, please visit www.senzagen.com

 

 

SenzaGen invites to a Live Session at the Facebook group “Aktier – Småbolagsjakten”

SenzaGen will host a live Question and Answer session with the management of the company May 16 between 19:00 – 20:00 CET

“Aktier – Småbolagsjakten” is the largest Facebook group in the Nordic region, focusing on publicly traded small companies. The group has over 35 000 members.

During the Live Session all questions and answers will be in English. Participants will have the opportunity to ask questions directly to company management including Chairman Carl Borrebaeck and CEO Anki Malmborg Hager.

To participate in the session, you must first become a member of the Facebook group “Aktier – Småbolagsjakten”. It is recommended that you submit a membership request at least one day in advance of the presentation to ensure you can participate in the event.

 

To join the group:

  1. Go to https://www.facebook.com/groups/smabolagsjakten
  2. Click the green “+ Join Group” button
  3. You will receive a notification on Facebook when your application to the group is accepted

 

For more information, please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822

 

About GARD™
GARD is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have over 90 percent reliability. This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75 percent. SenzaGen’s tests are also capable of measuring the potency of a substance’s allergenic properties. Consequently, GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.

About SenzaGen
SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company’s patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit www.senzagen.com

 

SenzaGen AB are listed on Nasdaq First North in Stockholm and FNCA is the company’s Certified Adviser. For more information, please visit www.senzagen.com

Successful outcome at the Future of Swedish and Danish Life Science day

We wish to thank Kemivärlden Biotech and Medicon Village for Thursday’s event “The Future of Swedish and Danish Life Science”, many interesting areas within precision medicine and big data were covered, not least within genomics.

Life sciences and information technologies have become more and more connected to make patient’s life better; a perfect example on this is SenzaGen’s in vitro safety testing based on genomics. By argumenting on how the company’s GARD™ technology can improve patient’s life, and how the technology can contribute to establish a new industry standard for animal free safety testing, SenzaGen’s Chief Commercial Officer, Anna Chérouvrier Hansson, won the Dragons Den pitch at The Future of Swedish and Danish Life Science.

-We’re very happy and proud to be recognized as a game changer in the industry, contributing to a safer patient environment, says Anna.
The prize, a ticket to the One Nucleus Genesis conference in London will support SenzaGen’s development of coming closer to the goal of placing a new industry standard.

 

For more information
Anki Malmborg Hager, CEO
SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822

 

Thank you for a great Society of Toxicology and ToxExpo 2018!

We would like to extend a great thank you to all customers, partners, friends and collaborators for a great SOT and ToxExpo 2018!

We had record numbers both in the audience for the presentation, at the poster presentation on validation for OECD and at the booth. We are very happy and proud to see the rapidly growing interest for SenzaGen and our GARD products and wish to thank you all for your shown interest!

A webinar with the presentation from SOT will be held for those interested on Tuesday March 27 at 11:30 am.

Presentation pdf available here

Poster on validation available here

Register for webinar here.
The presentation will be held in English

Thank you and we look forward to future collaborations!

 

For more information:
Anki Malmborg Hager, CEO
SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822

 

 

 

 

Conclusive data on predictive performance of GARD™ in highly regarded scientific journal

SenzaGen announces today that research on the conformal prediction of the GARD™ assay has been published in the distinguished peer reviewed journal Toxicology in Vitro. The research presented in the publication proves that, as the first in vitro model for prediction of the skin sensitizing potential of chemicals, GARD™ is now capable of providing a statistically valid measure of uncertainty for each individual prediction, thus allowing for classification of skin sensitizers with confidence. Consequently, GARD™ can meet the growing needs of high safety skin sensitization testing and particularly since there is now proof that all chemical reactivity domains, as well as pre- and pro-haptens are within GARD’s applicability domain. 

In the publication, Predicting skin sensitizers with confidence — Using conformal prediction to determine applicability domain of GARD™, a research group from Lund University, Swetox and SenzaGen reports its successful work on implementing a mathematical framework based on conformal prediction into GARD™ for the purpose of defining the applicability domain of the assay, something often neglected by test developers. Investigation of historical data within the framework demonstrates that all hitherto tested chemical reactivity domains, as well as pre- and pro-haptens are within the applicability domain of GARD, and can be predicted with a high degree of confidence. The results of this research demonstrate that the multivariate genomic biomarker signature, the unique technology of GARD makes it applicable across various chemical reactivity domains.

The mathematical framework in this implementation defines the applicability domain in terms of similarity to the samples used for model development and is capable of providing a statistically valid measure of uncertainty associated with each prediction. Furthermore, it also delivers a warning if a specific test sample is outside the region where the model is capable of generating a reliable prediction. Similar to the field of QSAR modelling, this information should be a minimal requirement for a successful validation also of in vitro models.

As the first in vitro model for prediction of skin sensitizing potential of chemicals, GARD™ is now capable of providing a statistically valid measure of uncertainty for each individual prediction, thus allowing for classification of skin sensitizers with even higher confidence. These scientific findings will benefit the chemical industry by providing better guidance of what test to use for different substances in different chemical domains and demonstrates the even broader applicability of GARD.

Full article:  Predicting skin sensitizers with confidence — Using conformal prediction to determine applicability domain of GARD Forreryd A., Norinder U., Lindberg T., Lindstedt M.  
https://www.sciencedirect.com/science/article/pii/S0887233318300237?via%3Dihub


For more information:
Anki Malmborg Hager, CEO, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822

 

About GARD™
GARD is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have over 90% reliability. This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75%. SenzaGen’s tests are also capable of measuring the potency of a substance’s allergenic properties. Consequently, GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.

About SenzaGen
SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company’s patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit www.senzagen.com

News post as pdf

New colleague at senzaGen

Welcome Andy Forreryd

Andy has started his position as Scientist with us here at SenzaGen after defending his doctoral thesis GARD – Genomic Allergen Rapid Detection, From Biomarker Discovery towards a State-of-the-art Testing Platform for Chemical Sensitizers at the Department of Immunotechnology, Lund University.

Andy strengthens SenzaGen’s scientific team with his genuine expertise on the GARD platform, which formed the basis for his thesis. Andy is a specialist in biomarker discovery and statistical analysis of multivariate genomic data and has long experience in both cell culturing and in various technologies for gene expression measurements. He also has great experience in communicating research to both a scientific and public audience.

As The faculty opponent of the doctoral thesis, Dr Gavin Maxwell, stated when starting his opposition: “The thesis in one of the most complete analyses in the field”. We can only agree.

We are very happy to have you in our team, Andy!

 

Link to thesis

GARD – Genomic Allergen Rapid Detection, From Biomarker Discovery towards a State-of-the-art Testing Platform for Chemical Sensitizers at the Department of Immunotechnology, Lund University.

 

The Immunotoxicity testing in the 21th century seminar

Welcome to the seminar

Immunotoxicity testing in the 21th century – recent developments within prediction of immunotoxicity using alternative methods.

The seminar will take place at the Medicon Village Aula (Hörsalen) on November 23, 2017 with the support from SenzaGen and Medicon village

Program:

13.15-13.30     Welcome
Prof. Malin Lindstedt, Dept. of Immunotechnology
Kerstin Jakobsson, Vice President, Medicon Village

13.30-14.00     From pathways to people: applying the skin sensitization adverse outcome pathway (AOP) 
Dr. Gavin Maxwell, Unilever’s Safety & Environmental Assurance centre, UK

14.00-14.30     Towards an AOP for chemical respiratory allergy
Prof. Ian Kimber, University of Manchester, UK

14.30-15.00     Coffee

15.00-15.30     Application of novel in vitro methods for the discovery of safe innovative medicines
Dr Jorrit Hornberg, Discovery Safety at AstraZeneca

15.30-16.00     Application of the AOP concept to structure the available in vivo and in vitro mechanistic data for allergic sensitization to food protein
Dr Erwin Roggen, 3Rs Management and Consulting ApS

16.00-16.30     Progress towards GARDskin validation and GARDair implementation
Dr Henrik Johansson, SenzaGen AB

Please register before Nov 15 to maria.klement@immun.lth.se

Link to program

Research on GARDprotein published in highly reputed scientific journal

SenzaGen announces that research findings that support the development of a new application area for the company’s test platform GARDTM have been published in the highly reputed journal Toxicology in Vitro. The research described in the publication constitutes the basis of GARDprotein – a test method currently being developed to be able to eliminate allergy-inducing proteins from today’s and tomorrow’s foodstuffs.

In the publication, An alternative biomarker-based approach for the prediction of proteins known to sensitize the respiratory tract, a research group from Lund University describes its successful work on the identification of a unique set of genes, gene signature, that makes it possible to evaluate the allergenic characteristics of proteins. This gene signature constitutes the basis of the development of GARDprotein, a test that has the potential to meet the growing needs of the food industry to avoid allergy-inducing substances in their products.

As previously announced, a scientific evaluation of GARDprotein has already been carried out. The positive results of this evaluation were recently announced at The 3rd ImpARAS Conference in Helsingør, Denmark. The results show that with a high degree of accuracy and reliability the test method can reduce the risk that proteins in food are incorrectly categorized as allergenic or that their allergenic properties are not detected in time.

The article :
An alternative biomarker-based approach for the prediction of proteins known to sensitize the respiratory tract. Zeller KS, Johansson H, Lund TØ, Kristensen NN, Roggen EL, Lindstedt M.

Published in Toxicology In Vitroonline available via this link:
https://www.ncbi.nlm.nih.gov/pubmed/29017774

For more information, please contact
Anki Malmborg Hager, CEO, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822

SenzaGen CEO Anki Malmborg Hager presents at Swetox conference on future research without animal testing

SenzaGen’s CEO, Anki Malmborg Hager, gives a presentation today on October 17, entitled: A new, animal-free allergy test with the goal of becoming a “golden standard” for risk assessment in the cosmetics and chemical industry. An innovation company with the next generation tests tells their story. The presentation will take place during the SWETOX conference at Hasselbacken in Stockholm

The conference, The Future on Research on Animal-Free Methods, is organized by SWETOX and is part of the communication “New Animal-Free Methods to Meet the Need for Safe Chemicals” funded by the Research Council FORMAS. SWETOX visions on reaching A Safe Chemical World and Toxicological Risk Assessment Without Animal Experiments, will be the starting point of the day.

The conference aim is to bring innovative people together and it is led by speakers from several pioneering research areas in animal-free research. The conference also addresses the political arena with closing discussions with Swedish politicians on site.

SWETOX is a national research centre for toxicology, a collaboration between eleven Swedish universities. The hub of the cooperation is a state-of-the-art and well-equipped facility in Gärtuna, outside Södertälje.

For more information about the conference (Swedish)
http://swetox.se/event/swetox-replacement-workshop/

For more information
Anki Malmborg Hager, vd, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822